Description
Febuxostat displays a variety of beneficial properties, including anti-inflammatory, anti-hyperuricemic, antidepressant, and nephroprotective activities. Febuxostat inhibits xanthine oxidase, preventing the generation of uric acid; as a result, it is used clinically to treat gout. In vitro, febuxostat inhibits MCP-1 and ROS production through activation of MAPK phosphatase. In vivo, febuxostat decreases oxidative stress and endoplasmic reticular stress, preventing increases in serum creatine and occurrence of renal tubular injury and fibrosis during renal ischemia. Additionally, this compound decreased immobility time during a forced swim test in animal models of depression.
References
Nomura J, Busso N, Ives A, et al. Febuxostat, an Inhibitor of Xanthine Oxidase, Suppresses Lipopolysaccharide-Induced MCP-1 Production via MAPK Phosphatase-1-Mediated Inactivation of JNK. PLoS One. 2013 Sep 25;8(9):e75527. PMID: 24086554.
Karve AV, Jagtiani SS, Chitnis KA. Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice. Indian J Pharmacol. 2013 May-Jun;45(3):244-7. PMID: 23833366.
Tsuda H, Kawada N, Kaimori JY, et al. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. Biochem Biophys Res Commun. 2012 Oct 19;427(2):266-72. PMID: 22995295.
Bisht M, Bist SS. Febuxostat: a novel agent for management of hyperuricemia in gout. Indian J Pharm Sci. 2011 Nov;73(6):597-600. PMID: 23112391.
